Gerischer, L. M., Schröder-Braunstein, J., Wabnitz, G. H., & Meisel, A. (2026). Reply to letter: “Limitations of complement activity assays as biomarkers for Ravulizumab therapeutic monitoring” by Saccà and Pelto Regarding “Inhibition of classical and alternative complement pathway by Ravulizumab and Eculizumab”. Annals of Clinical and Translational Neurology, 13(6), . https://doi.org/10.1002/acn3.70403
Cita Chicago Style (17a ed.)Gerischer, Lea Morrin, Jutta Schröder-Braunstein, Guido H. Wabnitz, y Andreas Meisel. "Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”." Annals of Clinical and Translational Neurology 13, no. 6 (2026). https://doi.org/10.1002/acn3.70403.
Cita MLA (9a ed.)Gerischer, Lea Morrin, et al. "Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”." Annals of Clinical and Translational Neurology, vol. 13, no. 6, 2026, https://doi.org/10.1002/acn3.70403.